EDAP TMS SA ADR(FOCL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.04 | Insider Own | 0.53% | Shs Outstand | 37.5M | Perf Week | -3.09% |
| Market Cap | 0.15B | Forward P/E | - | EPS next Y | 25.91% | Insider Trans | 173.45% | Shs Float | 37.3M | Perf Month | -14.29% |
| Enterprise Value | 0.17B | PEG | - | EPS next Q | -0.22 | Inst Own | 39.42% | Short Float | 0.76% | Perf Quarter | -14.11% |
| Income | -0.04B | P/S | 2.21 | EPS this Y | -24% | Inst Trans | 0.44% | Short Ratio | 2.69 | Perf Half Y | 3.03% |
| Sales | 0.07B | P/B | - | EPS next 5Y | 12.03% | ROA | -50.16% | Short Interest | 0.28M | Perf YTD | 24.01% |
| Book/sh | -0.09 | P/C | 7.1 | EPS past 3/5Y | -106.02% -63.72% | ROE | -263.75% | 52W High | -36.25% ($6.40) | Perf Year | 69.29% |
| Cash/sh | 0.57 | P/FCF | - | Sales past 3/5Y | 6.9% 8.3% | ROIC | -111.73% | 52W Low | 133.14% ($1.75) | Perf 3Y | -40.61% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -81.03% | Gross Margin | 48.73% | Volatility(W/M) | 3.93% 5.21% | Perf 5Y | -33.11% |
| Dividend TTM | - | EV/Sales | 2.5 | Sales Y/Y TTM | - | Oper. Margin | -39.32% | ATR (14) | 0.22 | Perf 10Y | 40.21% |
| Dividend Ex-Date | - | Quick Ratio | 1.38 | EPS Q/Q | -127.3% | Profit Margin | -56.25% | RSI (14) | 31.28 | Recom | 1.8 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.6 | Sales Q/Q | -27.49% | SMA20 | -3.55% ($4.23) | Beta | -0.04 | Target Price | $8.8 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -19.93% ($5.1) | Rel Volume | 0.37 | Prev Close | $4.11 |
| Employees | 289 | LT Debt/Eq | - | EPS/Sales Surpr. | -81.23% -12.49% | SMA200 | -2.94% ($4.2) | Avg Volume(3M) | 0.11M | Price | $4.08 |
| IPO | 1997/8/1 | Option/Short | Yes/Yes | Trades | 226 | Volume | 39,592 | Change | -0.73% |
Company
FOCL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩺 A healthcare company developing robotic-based local therapy medical devices. Its core offering is a non-invasive treatment platform that combines focused ultrasound technology with imaging, treatment planning, and robotic precision control, with a focus on treating localized lesions such as those in the prostate. It is a specialized medical device company headquartered in France that supplies medical devices to the global market.
Over the past 1 year, roughly in the middle
36% below its 1-year high.
FOCL has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -24.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -40.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 39.4%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $153M.
FOCL $153M PER -
MCK $105B PER 24.1
COR $62B PER 24.0
CAH $54B PER 32.1
FAQ
What kind of company is FOCL?
FOCL belongs to the Healthcare sector and operates in the Medical Distribution industry.
What is the market cap of FOCL?
The market cap of FOCL is approximately $153M, ranking 4,275 within its sector.
What is the 52-week high and low for FOCL?
FOCL has recorded a 52-week high of $6.40 and a low of $1.75.
